Combining chemoradiotherapy with anti-PD-1 immunotherapy has shown encouraging results in cancers such as NSCLC, gastric cancer, breast cancer, and hematological malignancies. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.